It is unclear how well glucose-lowering drugs work in comparison to metformin to keep target glycated haemoglobin levels in people with type 2 diabetes. We examined the efficacy of four routinely prescribed glucose-lowering drugs in a trial comprising individuals with type 2 diabetes of less than 10 years’ history, metformin therapy, and glycated haemoglobin levels of 6.8 to 8.5%.
the group of search conducted at The GRADE Study Research Group
Participants were given either the insulin glargine U-100 (hereafter referred to as “glargine”), the sulfonylurea glimepiride, the glucagon-like peptide-1 receptor agonist liraglutide, or the dipeptidyl peptidase 4 inhibitor sitagliptin.
A total of 5047 people who had taken metformin for type 2 diabetes were monitored for a mean of 5.0 years. Of these, 19.8% were Black and 18.6% were Hispanic or Latinx. The rates with glargine (26.5 per 100 participant-years) and liraglutide (26.1) were comparable and lower than those with glimepiride (30.4) and sitagliptin (P0.001 for a global test of differences across groups). The cumulative incidence of a glycated haemoglobin level of 7.0% or higher (the primary metabolic outcome) varied significantly among the four groups (38.1). Regarding a glycated haemoglobin level higher than 7.5% (the secondary outcome), the variations between the groups mirrored those of the primary result.
When used with metformin, all four drugs lowered glycated haemoglobin levels. However, obtaining and maintaining target glycated haemoglobin levels was significant, albeit somewhat, easier with glargine and liraglutide.
Now if you are Doctor who deals with diabetic patients it’s very important to understand which medication is good this is a very important factor if you want to understand the patient’s complications.
Make your clinic smart with INIGIMA Cloud diagnosis more details
Credit Source https://www.nejm.org/doi/full/10.1056/NEJMoa2200436?query=recirc_curatedRelated_article